Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Alumis

Request full access

Developing precision medicines for autoimmune diseases

South San Francisco, United StatesFounded 2021Biotech & Life Sciences

About Alumis

Alumis is a healthcare startup that focuses on developing precision therapies for patients suffering from immune-mediated diseases. The company operates in the biotechnology and pharmaceutical market, specifically targeting the niche of immunologic diseases. Alumis' business model is centered around the development and commercialization of innovative therapies, which are designed to improve clinical outcomes for patients.

The company's approach is rooted in a deep understanding of immunologic diseases and is driven by the principle of delivering the right medicine to achieve the best clinical outcome. Alumis uses precision medicine, a method that allows doctors to select treatments that are most likely to help patients based on a genetic understanding of their disease. This approach enables the company to select the right targets, molecules, indications, patients, endpoints, and potential combinations to optimize patient outcomes.

Alumis' revenue model is likely based on the sales of these developed therapies, either directly or through partnerships with other healthcare providers or pharmaceutical companies. The company may also generate income through licensing its technologies or through strategic partnerships.

In summary, Alumis is a biotech startup that uses precision medicine to develop therapies for immune-mediated diseases, aiming to improve patient outcomes through targeted treatment strategies.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2024
Employees
230
Open positions
None listed
Dealroom signal
91.6/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Precision Medicine, Rumoured $1B, Biotech and Pharma, Hard Tech, Woman Founder, DT and LS, science-based
Business model
SaaS
Client focus
B2B
Investment activity
1 company, latest Feb 2025
Capital deployed
—
Preferred round
ACQUISITION

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO EQUITYOther financing Mar 2026 $169M — Deep Track Capital ↗
POST IPO EQUITYOther financing Jan 2026 $345M — Undisclosed ↗
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Alumis website traffic

Latest recorded traffic for Alumis is 13K monthly website visits, down 56.7% over the last three months. Alumis's team grew 0.9% over the past year.

Latest monthly visits13K 3-month web change-56.7% 1-year team growth+0.9%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Alumis in the South San Francisco ecosystem

Live from Dealroom

The Alumis office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

Series B and later11 investors entered at this stage

  • SR One
  • venBio Partners
  • Ally Bridge Group
  • Samsara BioCapital
  • Nextech
  • Omega Funds
  • Cormorant Asset Management
  • Lilly Asia Ventures
  • Piper Sandler
  • HBM Healthcare Investments
  • Deep Track Capital
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Alumis’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.